The combined activity of bortezomib and cetuximab in EGFR-positive solid cancers is unknown, though it is reasonable to postulate that this combination could be synergistic, given the preclinical observations that bortezomib upregulates EGFR expression in cancer cells. This evidence concerns the gene EGFR and cancer.